<DOC>
	<DOCNO>NCT03092999</DOCNO>
	<brief_summary>Evaluate potential effect hepatic impairment pharmacokinetics , safety tolerability BAY1002670 ( vilaprisan )</brief_summary>
	<brief_title>Effect Hepatic Impairment Pharmacokinetics , Safety Tolerability BAY1002670 ( Vilaprisan )</brief_title>
	<detailed_description />
	<mesh_term>Leiomyoma</mesh_term>
	<criteria>For subject : The informed consent must sign study specific test procedures do White/Caucasian men woman age 18 79 year ( inclusive ) Body mass index ( BMI ) : 18 34 kg/m2 ( inclusive ) Ability understand follow studyrelated instruction Women men reproductive potential must agree use adequate contraception sexually active . This applies time period signing informed consent form three month administration study drug . Subjects must agree use two nonhormonal method contraception simultaneously ( e.g . condom diaphragm , plus spermicide ) throughout study sexually active . This required safe contraception achieve permanent method , hysterectomy , bilateral fallopian tube ligation vasectomy . For subject hepatic impairment : Subjects document liver cirrhosis confirm histopathology , laparoscopy , fibroscan , ultrasound Subjects hepatic impairment ( ChildPugh A B ) Subjects stable liver disease , i.e . ChildPugh class last 2 month Any relevant disease within 4 week prior study drug administration require medical treatment Known severe allergy , nonallergic drug reaction , multiple drug allergy Use contain sex hormone within 4 week six month first study drug administration Use CYP3A4 Pglycoprotein inhibitor inducer Use drug may affect absorption Major change medication &lt; 2 week prior study drug administration Deviations normal range physical examination , gynecological examination , clinical chemistry , hematology , urinalysis consider relevant investigator Any criterion , opinion investigator , make study participation unadvisable scientific , compliance , safety , medical reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>